CoChat

ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

Flynn, Michael J., Zammarchi, Francesca, Tyrer, Peter C., Akarca, Ayse U., Janghra, Narinder, Britten, Charles E., Havenith, Carin E.G., Levy, Jean-Noel, Tiberghien, Arnaud, Masterson, Luke A., Barry, Conor, D'Hooge, Francois, Marafioti, Teresa, Parren, Paul W.H.I., Williams, David G., Howard, Philip W., van Berkel, Patrick H., Hartley, John A. · 2016 · Molecular Cancer Therapeutics
Cited by 124

The DOI matches its Crossref record.

Abstract

Despite the many advances in the treatment of hematologic malignancies over the past decade, outcomes in refractory lymphomas remain poor. One potential strategy in this patient population is the specific targeting of IL2R-α (CD25), which is overexpressed on many lymphoma and leukemic cells, using antibody–drug conjugates (ADC). ADCT-301 is an ADC composed of human IgG1 HuMax-TAC against CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead with a drug–antibody ratio (DAR) of 2.3. ADCT-301 binds human CD25 with picomolar affinity. ADCT-301 has highly potent and selective cytotoxicity against a panel of CD25-expressing human lymphoma cell lines. Once internalized, the released warhead binds in the DNA minor groove and exerts its potent cytotoxic action via the formation of DNA interstrand cross-links. A strong correlation between loss of viability and DNA cross-link formation is demonstrated. DNA damage persists, resulting in phosphorylation of histone H2AX, cell-cycle arrest in G2–M, and apoptosis. Bystander killing of CD25-negative cells by ADCT-301 is also observed. In vivo, a single dose of ADCT-301 results in dose-dependent and targeted antitumor activity against both subcutaneous and disseminated CD25-positive lymphoma models. In xenografts of Karpas 299, which expressed both CD25 and CD30, marked superiority over brentuximab vedotin (Adcetris) is observed. Dose-dependent increases in DNA cross-linking, γ-H2AX, and PBD payload staining were observed in tumors in vivo indicating a role as relevant pharmacodynamic assays. Together, these data support the clinical testing of this novel ADC in patients with CD25-expressing tumors. Mol Cancer Ther; 15(11); 2709–21. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-16-0233

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 124

Metadata

Authors
Flynn, M. J., Zammarchi, F., Tyrer, P. C., Akarca, A. U., Janghra, N., Britten, C. E., Havenith, C. E. G., Levy, J.-N., Tiberghien, A., Masterson, L. A., Barry, C., D'Hooge, F., Marafioti, T., Parren, P. W. H. I., Williams, D. G., Howard, P. W., van Berkel, P. H., & Hartley, J. A.
Venue
Molecular Cancer Therapeutics
Published
2016-11-01
Volume
15
Issue
11
Pages
2709-2721
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2513682949
Cited by
124
References
0
FWCI
6.09
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. https://app.cochat.ai/papers/10.1158/1535-7163.mct-16-0233
The paper
Flynn, M. J., Zammarchi, F., Tyrer, P. C., Akarca, A. U., Janghra, N., Britten, C. E., Havenith, C. E. G., Levy, J.-N., Tiberghien, A., Masterson, L. A., Barry, C., D'Hooge, F., Marafioti, T., Parren, P. W. H. I., Williams, D. G., Howard, P. W., van Berkel, P. H., & Hartley, J. A. (2016). ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-16-0233

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.